NASDAQ:RETA
Delisted
RETA Stock News
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Los Angeles, California--(Newsfile Corp. - December 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmace
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United S
DEC. 14 DEADINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.– RETA
11:57am, Tuesday, 08'th Dec 2020
NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ:
New York, New York--(Newsfile Corp. - December 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwee
Los Angeles, California--(Newsfile Corp. - December 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharma
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Offering
12:54pm, Friday, 04'th Dec 2020
PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing o
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 an
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
09:48pm, Tuesday, 01'st Dec 2020
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has p
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
04:03pm, Tuesday, 01'st Dec 2020
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action that has been
New York, New York--(Newsfile Corp. - November 29, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwe
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action that has
New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between
New York, New York--(Newsfile Corp. - November 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between
Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmac
